Here are four highlights:
1. Xtant anticipates its third quarter revenue to be between $23 million and $23.3 million.
2. This expected revenue represents a 10 percent to 11.5 percent increase compared to pro forma third quarter of 2015 revenue.
3. Additionally, the anticipated revenue reflects a sequential increase of 7.2 percent to 8.6 percent compared to second quarter 2016 revenue.
4. Xtant Medical manufactures regenerative medicine products.
More articles on devices:
Are Stryker’s hip implants about to be recalled?
Medtronic, Philips Healthcare lead US patient monitoring device market: 5 notes
SpineNevada offers advanced imaging with InMotion Diagnostics — 6 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
